Alteplase: Difference between revisions
(Redirected page to Thrombolysis in Acute Ischemic Stroke (tPA)) |
ClaireLewis (talk | contribs) No edit summary |
||
| Line 1: | Line 1: | ||
==Administration== | |||
*Type: [[Thrombolytic]] | |||
*Dosage Forms: | |||
*Routes of Administration: IV | |||
*Common Trade Names: tPA | |||
==Adult Dosing== | |||
*Acute [[MI]]: | |||
**>67kg: 15mg IV over 1-2min; then 50mg IV over 30min; then 35mg over next 60min (i.e. 100mg over 1.5hr) | |||
**≤67kg: 15mg IV over 1-2min; then 0.75 mg/kg (max 50mg) IV over 30 min; then 0.5 mg/kg over 60min (max 35 mg) | |||
*Acute [[ischemic stroke]]: | |||
**0.9mg/kg IV (max 90mg total) | |||
***10% of dose is administered as bolus; rest is given over 60min | |||
*Massive [[PE]]:: | |||
**100mg IV over 2hr OR 0.6mg/kg over 2min | |||
**See also: [[EBQ:Thrombolysis in Pulmonary Embolism Metanalysis]] | |||
*Arterial thrombosis: | |||
**1.5 mg/hour by transcatheter intra-arterial infusion until lysis of thrombus | |||
==Pediatric Dosing== | |||
*[[PE]]: 0.5 mg/kg/hour IV, for a maximum of 6 hours, in addition to heparin | |||
==Special Populations== | |||
*[[Drug Ratings in Pregnancy|Pregnancy Rating]]: C | |||
*[[Lactation risk categories|Lactation risk]]: Infant risk cannot be ruled out | |||
*Renal dosing: not defined | |||
*Hepatic dosing: not defined | |||
==Contraindications== | |||
*Allergy to class/drug | |||
*Bleeding diathesis | |||
*Active internal bleeding | |||
*Current intracranial hemorrhage, subarachnoid hemorrhage | |||
*Intracranial neoplasm, arteriovenous malformation, aneurysm, or other conditions that may increase the risk of intracranial bleeding | |||
*Recent (<3 mo) intracranial or intraspinal surgery | |||
*Recent (<3 mo) serious head trauma | |||
*Recent (<3 mo) stroke (for patients being treated for MI or PE) | |||
*Severe uncontrolled hypertension | |||
==Adverse Reactions== | |||
===Serious=== | |||
*Bleeding! | |||
*GI bleed | |||
*Pericardial effusion, pericarditis, cardiac tamponade | |||
*Intracranial hemorrhage, cerebral herniation | |||
*Stroke, seizure | |||
*Anaphylaxis, angioedema | |||
*Pulmonary edema, pleural effusion | |||
*Cardiac dysrhythmia | |||
===Common=== | |||
==Pharmacology== | |||
*Onset of action: 30-60 minutes | |||
*Half-life: 26.5 to 46 minutes | |||
*Metabolism: Liver | |||
*Excretion: | |||
==Mechanism of Action== | |||
*Tissue plasminogen activator (TPA): binds fibrin, enhances conversion of plasminogen to plasmin thus initiating fibrinolysis | |||
==Comments== | |||
==See Also== | |||
*[[Thrombolytics]] | |||
*[[Thrombolysis in Acute Ischemic Stroke (tPA)]] | |||
*[[EBQ:Thrombolysis in Pulmonary Embolism Metanalysis]] | |||
*[[Acute arterial ischemia]] | |||
*[[STEMI]] | |||
==References== | |||
<references/> | |||
[[Category:Pharmacology]] | |||
Revision as of 21:09, 22 December 2016
Administration
- Type: Thrombolytic
- Dosage Forms:
- Routes of Administration: IV
- Common Trade Names: tPA
Adult Dosing
- Acute MI:
- >67kg: 15mg IV over 1-2min; then 50mg IV over 30min; then 35mg over next 60min (i.e. 100mg over 1.5hr)
- ≤67kg: 15mg IV over 1-2min; then 0.75 mg/kg (max 50mg) IV over 30 min; then 0.5 mg/kg over 60min (max 35 mg)
- Acute ischemic stroke:
- 0.9mg/kg IV (max 90mg total)
- 10% of dose is administered as bolus; rest is given over 60min
- 0.9mg/kg IV (max 90mg total)
- Massive PE::
- 100mg IV over 2hr OR 0.6mg/kg over 2min
- See also: EBQ:Thrombolysis in Pulmonary Embolism Metanalysis
- Arterial thrombosis:
- 1.5 mg/hour by transcatheter intra-arterial infusion until lysis of thrombus
Pediatric Dosing
- PE: 0.5 mg/kg/hour IV, for a maximum of 6 hours, in addition to heparin
Special Populations
- Pregnancy Rating: C
- Lactation risk: Infant risk cannot be ruled out
- Renal dosing: not defined
- Hepatic dosing: not defined
Contraindications
- Allergy to class/drug
- Bleeding diathesis
- Active internal bleeding
- Current intracranial hemorrhage, subarachnoid hemorrhage
- Intracranial neoplasm, arteriovenous malformation, aneurysm, or other conditions that may increase the risk of intracranial bleeding
- Recent (<3 mo) intracranial or intraspinal surgery
- Recent (<3 mo) serious head trauma
- Recent (<3 mo) stroke (for patients being treated for MI or PE)
- Severe uncontrolled hypertension
Adverse Reactions
Serious
- Bleeding!
- GI bleed
- Pericardial effusion, pericarditis, cardiac tamponade
- Intracranial hemorrhage, cerebral herniation
- Stroke, seizure
- Anaphylaxis, angioedema
- Pulmonary edema, pleural effusion
- Cardiac dysrhythmia
Common
Pharmacology
- Onset of action: 30-60 minutes
- Half-life: 26.5 to 46 minutes
- Metabolism: Liver
- Excretion:
Mechanism of Action
- Tissue plasminogen activator (TPA): binds fibrin, enhances conversion of plasminogen to plasmin thus initiating fibrinolysis
Comments
See Also
- Thrombolytics
- Thrombolysis in Acute Ischemic Stroke (tPA)
- EBQ:Thrombolysis in Pulmonary Embolism Metanalysis
- Acute arterial ischemia
- STEMI
